Research Unit in Experimental Pharmacology, Department of Functional Sciences, School of Medicine, Universidad Centroccidental Lisandro Alvarado (UCLA), Barquisimeto, Venezuela.
Indian J Pharmacol. 2011 Nov;43(6):683-8. doi: 10.4103/0253-7613.89826.
The in vivo and in vitro antitumor activity of kaurenic acid [kaur 16-en-19 oic acid] (KA) in melanoma was evaluated in a murine model in comparison with taxol (Tx).
B16F1 melanoma was developed in C57BL/6 mice and cell cultures. Survival test, tumor growth, dissected-tumor measurements, histology, cytoxicity assay on cultured cells, and changes of apoptotic gene expression at mRNA level were analyzed.
KA showed antitumor effect in vivo and in vitro and compared with Tx, its antimelanoma activity was greater (P < 0.001). These results were confirmed by morphological analysis (P < 0.001). In melanoma cell cultures, KA IC(50) was 0.79 μM vs. 18.94 μM for Tx (P < 0.001). RT-PCR analysis demonstrated that Bcl-xL mRNA expression was altered in B16F1 mouse melanoma cells obtained from mice treated with either KA or Tx.
The data suggest that KA is active in animal melanoma models, both in vitro and in vivo, being its cytotoxic effects stronger than those exhibited by Tx. Further trials should be conducted to elucidate its mechanism of action in melanoma with respect to necrosis or apoptotic processes. Our results support other evidences indicating that KA is a potential chemotherapeutic agent against cancer that has to be widely explored.
在黑色素瘤的小鼠模型中,评估贝壳杉烯酸(kaur 16-en-19 羧酸)(KA)与紫杉醇(Tx)的体内和体外抗肿瘤活性。
在 C57BL/6 小鼠中发展 B16F1 黑色素瘤和细胞培养物。进行生存试验、肿瘤生长、解剖肿瘤测量、组织学、培养细胞的细胞毒性测定以及分析凋亡基因表达的变化。
KA 显示出体内和体外的抗肿瘤作用,与 Tx 相比,其抗黑色素瘤活性更强(P < 0.001)。这些结果通过形态学分析得到证实(P < 0.001)。在黑色素瘤细胞培养物中,KA 的 IC(50)为 0.79 μM,而 Tx 为 18.94 μM(P < 0.001)。RT-PCR 分析表明,用 KA 或 Tx 处理的小鼠获得的 B16F1 小鼠黑色素瘤细胞中 Bcl-xL mRNA 表达发生改变。
数据表明 KA 在动物黑色素瘤模型中具有活性,无论是在体内还是体外,其细胞毒性作用均强于 Tx。应进一步进行试验以阐明其在黑色素瘤中与坏死或凋亡过程有关的作用机制。我们的结果支持其他表明 KA 是一种有潜力的针对癌症的化疗药物的证据,需要广泛探索。